Navigation Links
Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals

DUBLIN, March 16, 2010 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ; SHPGY), announces that it has received a Paragraph IV Notice Letter from Teva Pharmaceuticals USA, Inc. ("Teva") advising of the filing of an Abbreviated New Drug Application ("ANDA") for a generic version of Shire's 1 mg, 2mg, 3 mg, and 4mg guanfacine hydrochloride extended release tablets, INTUNIV(TM).

INTUNIV is protected by three FDA Orange Book listed patents: U.S. Patent No. 5,854,290, Use of Guanfacine in the Treatment of Behavioral Disorders; U.S. Patent No. 6,287,599 ("the '599 patent") and U.S. Patent No. 6,811,794 ("the '794 patent") both titled Sustained Release Pharmaceutical Dosage Forms with Minimized pH Dependent Dissolution Profiles. The three patents expire in 2015, 2020 and 2022, respectfully.

Shire is currently reviewing the details of Teva's Paragraph IV Notice Letter which was only directed to the '599 and '794 patents.

The Hatch-Waxman exclusivity period for INTUNIV runs until September 2, 2012 therefore, ANDAs for generic versions of INTUNIV cannot be approved prior to the end of that exclusivity period.

Under the Hatch-Waxman Act, Shire has 45 days from the receipt of the Notice Letter to determine if it will file a patent infringement suit. If Shire brings suit pursuant to the Hatch Waxman regulations, a stay of approval of up to 30-months will be imposed by the FDA on Teva's ANDA.

Notes to editors


Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website:


Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, the Company's results could be materially adversely affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of research, development, approval, reimbursement, manufacturing and commercialization of the Company's Specialty Pharmaceutical and Human Genetic Therapies products, as well as the ability to secure and integrate new products for commercialization and/or development; government regulation of the Company's products; the Company's ability to manufacture its products in sufficient quantities to meet demand; the impact of competitive therapies on the Company's products; the Company's ability to register, maintain and enforce patents and other intellectual property rights relating to its products; the Company's ability to obtain and maintain government and other third-party reimbursement for its products; and other risks and uncertainties detailed from time to time in the Company's filings with the Securities and Exchange Commission.

    For further information please contact:

    Investor Relations
    Clea Rosenfeld (Rest of the World), +44-1256-894-160;
    Eric Rojas (North America), +1-617-551-9715.

    Jessica Mann (Rest of the World), +44-1256-894-280;
    Matthew Cabrey (North America, Specialty Pharma), +1-484-595-8248.

SOURCE Shire Pharmaceutical

Back to top
SOURCE Shire Pharmaceutical
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Shire Supports Rare Disease Day 2010
2. Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease
3. Shire Provides Update on Biologics License Application (BLA) Filing for REPLAGAL(R) (agalsidase alfa) With the U.S. Food and Drug Administration (FDA)
4. Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease
5. New Shire Board Member
6. Shire Secures European Wide Label Extension for FOSRENOL(R) in Chronic Kidney Disease
7. New CapSure™ Cleanroom Wiper from Berkshire Corporation Captures and Retains 42 Times More Contaminant Particles
8. Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A/S on LNA Drug Platform
9. Santaris Pharma A/S Forms Strategic Alliance With Shire plc to Develop RNA-Based Medicines for the Treatment of Rare Genetic Disorders
10. Shire Initiates Two Adult ADHD Outreach Programs
11. Shire plc: Core Portfolio of Products Delivers 20% Sales Growth
Post Your Comments:
(Date:10/9/2015)... , Oct. 9, 2015 Governor ... clinical stage biopharmaceutical company focused on developing T-cell receptor ... high-paying jobs with a new expansion project. ... news for the commonwealth as 110 new, high-paying jobs ... Tom Wolf . "My budget proposal includes sustained funding ...
(Date:10/9/2015)...  Pulmatrix, Inc., (NASDAQ: PULM ) will be webcasting ... th Annual BIO Investor Forum on Tuesday, ... --> th Annual BIO Investor Forum ... pm EDT). --> Pulmatrix will be presenting ... on Thursday, October 15, 2015 at 8:30 am EDT. Additionally, ...
(Date:10/8/2015)... BELLINGHAM, Washington, USA, and CARDIFF, UK (PRWEB) , ... October 08, ... ... noninvasive light-based imaging technology to literally see inside the living brain, providing a new ... over time. , The work is reported by Woo June Choi and Ruikang Wang ...
(Date:10/8/2015)...  Genetic testing for mutations beyond those currently recommended ... couples at risk of having a child with cystic ... 2015 American Society of Human Genetics (ASHG) Annual Meeting, ... Maryland . The study is one of four ... are presenting at the conference this week demonstrating the ...
Breaking Biology Technology:
... Commercialization and Supply Agreement, Company to Host Conference Call at 12:30 p.m. ... ... 2007, LEXINGTON, Mass., Sept. 19 Indevus,Pharmaceuticals, Inc. (Nasdaq: ... acquisition of Esprit Pharma, has obtained the,United States rights to SANCTURA(R) and ...
... Ventures, Kleiner Perkins ... Ventures, Strong Endorsement of Technology Pioneer at Forefront of Developing No- ... Compromise Biofuels, ... renewable hydrocarbon biofuels, today,announced that it closed the first tranche of its $70 ...
... - IDF Launches New Guideline for the ... the new global guideline for diabetes care which,includes ... people with diabetes should have their blood glucose ... diabetes control and reduce the,risk of complications, particularly ...
Cached Biology Technology:
(Date:9/24/2015)... September 24, 2015 ... 2015 Kerv ( ... lanserar idag världens första kontaktlösa betalningsring på ... 77 000 GBP för massproduktion via crowdfunding.  ... ) , Kerv-bärare kan göra ...
(Date:9/10/2015)... , Sept. 10, 2015 Pursuant Health ... Wellness to create an interactive, image-based health risk ... and wellness kiosk.  The unique assessment quantifies user ... number that suggests an individual,s biological age based ... as measured by the kiosk. Comprised ...
(Date:9/8/2015)... BOSTON , Sept. 8, 2015  Affectiva, ... of Emotion as a Service, a new data ... Based on Affectiva,s highly accurate and ... and analytics capabilities, slated to transform industries such ... app development, retail, customer experience, online education, HR, ...
Breaking Biology News(10 mins):
... For the first time, researchers have been able to confine ... role in photosynthesis, without having to pin it down so ... first practical application to proteins of a recently developed technique, ... the dynamic behavior of the molecule for more than one ...
... system science disciplines recently gathered to address a major ... future? Of course, possible answers to this question ... conditions were to alter local vegetation, how would this ... questions with certainty would allow us to manage better ...
... , SEATTLE, WA March 10, 2010 -- The ... genome sequences of a human family of four. The findings ... the University of Luxembourg was published online today by Science ... benefit of sequencing entire families, including lowering error rates, identifying ...
Cached Biology News:
Request Info...
Recombinant Equine TNF-alpha/TNFSF1A, CF...
Recombinant Equine IL-4, CF...
actin from rabbit muscle Cell Biology Cytoskeletal Probes Actin and Actin Probes...
Biology Products: